PROVIREX Genome Editing Therapies
News &
Publications
LATEST NEWS
LATEST NEWSOur new scientific publication is now published in Plos One. In this publication we present an extensive preclinical evaluation of…
We took third place in the Göttingen Innovation Award 2023 in the category "Companies with up to 20 employees"! Many…
In rainy and stormy weather, the official ceremony for the start of the construction of the new tecHHub building for…
With this award, the Hamburg Chamber of Commerce (Handelskammer) recognises companies, institutions or individuals who are actively shaping the future…
Since August 2022, we have been setting up two completely new laboratories and registering them with the authorities to continue…
PROVIREX Genome Editing Therapies GmbH Hamburg and the University Medical Centre Hamburg-Eppendorf will receive R&D funding from the Hamburg Investment…
Triggering aggressive forms of leukaemia or an incurable spinal cord disease that leads to paralysis. HTLV-1 virus is the often…
Bioventure joins PROVIREX as a lead investor! IFB Innovationstarter GmbH also increases its investment as a co-investor. These investments will…
At an exclusive press event on October 27, 2022, at Factory Hammerbrooklyn, the official go-ahead was given to establish a…
PROVIREX started renting laboratories and office space in the Start-Up Labs Bahrenfeld on the DESY campus. The newly established workspace…
Researchers from Hamburg plan to use a new gene and cell method to transform the treatment of HIV patients in…
PROVIREX and Pantherna Therapeutics entered into a research collaboration to develop and evaluate Pantherna’s proprietary PTXxLNP delivery technology based on novel…
PROVIREX’s proprietary Brec1 technology enters clinical testing as a first-in-human phase Ib/IIa clinical trial (HIVcure) aiming to remove HIV-1 from infected…
Founding of the company PROVIREX Genome Editing Therapies GmbH
Scientific Publications
SCIENTIFIC PUBLICATIONS- Beschorner N, Künzle P, Voges M, Hauber I, Indenbirken D, Nakel J, Sanamjeet Virdi, Peter Bradtke, Niels Christian Lory, Michael Rothe, Maciej Paszkowski-Rogacz, Frank Buchholz, Adam Grundhoff, Axel Schambach, Christian Thirion, Hans-Willi Mittruecker, Julian Schulze zur Wiesch, Joachim Hauber, Jan Chemnitz (2024). Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1. PLoS ONE 19(3): e0298542. https://doi.org/10.1371/journal.pone.0298542.
- Rojo-Romanos, T., Karpinski, J., Millen, S., Beschorner, N., Simon, F., Paszkowski-Rogacz, M., Lansing, F., Schneider, P.M., Sonntag, J., Hauber, J., Thoma-Kress, A., and Buchholz, F. (2023). Precise Excision of HTLV-1 Provirus with a Designer-Recombinase. Molecular Therapy 31, 2266-2286.
- Karpinski, J., Hauber, I., Chemnitz, J., Schäfer, C., Paszkowski-Rogacz, M., Chakraborty, D., Beschorner, N., Hofmann-Sieber, H., Lange, U.C., Grundhoff, A., Hackmann, K., Schrock, E., Abi-Ghanem, J., Pisabarro, M.T., Surendranath, V., Schambach, A., Lindner, C., van Lunzen, J., Hauber, J., and Buchholz, F. (2016). Directed Evolution of a Recombinase that Excises the Provirus of Most HIV-1 Primary Isolates with High Specificity. Nature Biotechnology 34, 401-409.
- Meinke, G., Bohm, A., Hauber, J., Pisabarro, M.T., and Buchholz, F. (2016). Cre Recombinase and Other Tyrosine Recombinases. Chemical Reviews 116, 12785-12820.
- Abi-Ghanem, J., Chusainow, J., Karimova, M., Spiegel, C., Hofmann-Sieber, H., Hauber, J., Buchholz, F., and Pisabarro, M.T. (2013). Engineering of a Target Site-Specific Recombinase by a Combined Evolution- and Structure-Guided Approach. Nucleic Acids Research 41, 2394-2403.
- Buchholz, F., and Hauber, J. (2016). Antiviral Therapy of Persistent Viral Infection Using Genome Editing. Current Opinion in VIROLOGY 20, 85-91.
- Hauber, I., Hofmann-Sieber, H., Chemnitz, J., Dubrau, D., Chusainow, J., Stucka, R., Hartjen, P., Schambach, A., Ziegler, P., Hackmann, K., Schröck, E., Schumacher, U., Lindner, C., Grundhoff, A., Baum, C., Manz, M.G., Buchholz, F., and Hauber, J. (2013). Highly Significant Antiviral Activity of HIV-1 LTR-Specific Tre-Recombinase in Humanized Mice. PLOS Pathogens 9, e1003587.
- Buchholz, F., and Hauber, J. (2013). Engineered DNA Modifying Enzymes: Components of a Future Strategy to Cure HIV/AIDS. Antiviral Research 97, 211-217.
- Mariyanna, L., Priyardarshini, P., Hofmann-Sieber, H., Krepstakies, M., Walz, N., Grundhoff, A., Buchholz, F., Hildt, E., and Hauber, J. (2012). Excision of HIV-1 Proviral DNA by Recombinant Cell Permeable Tre-Recombinase. PLOS ONE 7, e31576.
- Buchholz, F., and Hauber, J. (2011). In Vitro Evolution and Analysis of HIV-1 LTR-Specific Recombinases. Methods 53, 102-109.
- Sarkar, I., Hauber, I., Hauber, J., and Buchholz, F. (2007). HIV-1 Proviral DNA Excision Using an Evolved Recombinase. Science 316, 1912-1915.